Last reviewed · How we verify

Formoterol Inhalant Powder

Imperial College London · Phase 1 active Small molecule

Formoterol Inhalant Powder is a Small molecule drug developed by Imperial College London. It is currently in Phase 1 development. Also known as: Oxis.

At a glance

Generic nameFormoterol Inhalant Powder
Also known asOxis
SponsorImperial College London
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Formoterol Inhalant Powder

What is Formoterol Inhalant Powder?

Formoterol Inhalant Powder is a Small molecule drug developed by Imperial College London.

Who makes Formoterol Inhalant Powder?

Formoterol Inhalant Powder is developed by Imperial College London (see full Imperial College London pipeline at /company/imperial-college-london).

Is Formoterol Inhalant Powder also known as anything else?

Formoterol Inhalant Powder is also known as Oxis.

What development phase is Formoterol Inhalant Powder in?

Formoterol Inhalant Powder is in Phase 1.

Related